Related Experiment Videos
Growth hormone treatment in short children
Insights
Pituitary human growth hormone (hGH) injections effectively treated short stature in children, showing significant growth in most participants within the first year without adverse effects. The treatment led to increased IGF-1 and IGF-2 levels, indicating positive metabolic responses.
Area of Science:
- Pediatric Endocrinology
- Growth Hormone Therapy
- Biochemistry
Background:
- Short stature affects numerous children, impacting physical development and psychosocial well-being.
- Growth hormone (GH) deficiency is a primary cause of idiopathic short stature.
- Pituitary-derived human growth hormone (hGH) is a critical treatment for growth disorders.
Purpose of the Study:
- To evaluate the efficacy and safety of pituitary hGH in treating children with short stature.
- To assess the growth response and biochemical markers after one year of hGH therapy.
- To identify factors influencing treatment response in pediatric patients.
Main Methods:
- A cohort of 31 children with short stature received daily subcutaneous injections of pituitary hGH (0.1 IU/kg/day).
- Study duration for presented data was one year, with ongoing monitoring for final height attainment.
- Biochemical markers including IGF-1, IGF-2, alkaline phosphatase, and procollagen III were measured.
Main Results:
- A significant growth response was observed in 29 out of 31 children (93.5%) within the first year.
- No adverse effects or antibody development were reported in any participants.
- An initial increase in IGF-1, IGF-2, alkaline phosphatase, and procollagen III levels was noted in responders.
- The most robust growth response correlated with the lowest endogenous pulsatile hGH secretion levels.
Conclusions:
- Subcutaneous pituitary hGH administration is a safe and effective treatment for short stature in children.
- The observed increases in IGF-1, IGF-2, and other markers suggest a positive anabolic response to hGH therapy.
- Individual response to hGH therapy may be influenced by baseline endogenous GH secretion patterns.
Abstract:
A study of 31 children with short stature was initiated in 1982. They received subcutaneous injections of pituitary hGH, 0.1 IU/kg/day; no adverse effects were seen and none of the patients acquired antibodies. Only the results of the first year are presented, as final height has not yet been attained. A high growth response was seen in 29 of the 31 children; they experienced an initial rise of IGF-1, IGF-2, alkaline phosphatase and procollagen III. The best response was obtained in the child with the lowest levels of endogenous pulsatile hGH secretion.